

# European Respiratory Society Annual Congress 2012

**Abstract Number:** 3531

**Publication Number:** P829

**Abstract Group:** 3.3. Mechanisms of Lung Injury and Repair

**Keyword 1:** COPD - management **Keyword 2:** Inflammation **Keyword 3:** Animal models

**Title:** Treatment with proteinase inhibitor, BbCI, modulates inflammatory response, mechanic alterations, and remodeling on elastase-induced emphysema in mice

Mr. Rafael 19611 Almeida-Reis dosreisrafael@gmail.com<sup>1</sup>, Mr. Bruno T.M. 19612 Oliveira brunotad@gmail.com<sup>1</sup>, Mr. Osmar A. 19627 Theodoro-Junior osmartheodoro@ig.com.br<sup>1</sup>, Mr. Leandro V. 19806 Oliva leandrooliva@hotmail.com<sup>1</sup>, Ms. Nathalia 19809 Pinheiro pinheiro.nathalia@gmail.com<sup>3</sup>, Dr. Marlon V. 19813 Brito marlonvilela@yahoo.com.br<sup>2</sup>, Dr. Fernanda D.Q.T. 19814 Lopes fernanda@experimental.fm.usp.br<sup>1</sup>, Dr. Carla M. 19815 Prado cmprado@gmail.com<sup>3</sup>, Dr. Milton A. 19816 Martins mmartins@usp.br MD<sup>1</sup>, Dr. Maria Luiza V. 19817 Oliva olivamlv@gmail.com<sup>2</sup> and Dr. Iolanda F.L.C. 19823 Tibério iocalvo@uol.com.br MD<sup>1</sup>. <sup>1</sup> Clinical Medicine, School of Medicine, University of São Paulo, SP, Brazil ; <sup>2</sup> Biochemistry, Federal University of São Paulo, Brazil and <sup>3</sup> Biological Sciences, Federal University of São Paulo, Diadema, Brazil .

**Body:** Bauhinia bauhinioides Cruzipain Inhibitor (BbCI) is a proteinase inhibitor that neutralizes neutrophil elastase and cathepsin G. The present study evaluated the capacity of BbCI in the treatment of elastase-induced emphysema. Methods: Mice received elastase intratracheally (ELA group) or saline (SAL group). Afterwards, mice were treated with BbCI (2 mg/kg) at days 1, 15 and 21 after elastase (ELABI group) or saline instillation (SALBI group). At day 28, mice were ventilated and respiratory resistance (Rrs), elastance (Ers), tissue elastance (Htis), tissue damping (Gtis), airway resistance (Raw), and exhaled nitric oxide (ENO) were analyzed, and BALF was obtained. We also quantified, mean linear intercept (Lm), elastic and collagen fibers. Results: In ELA group, there was a significant increase in the Ers, Rrs, Raw, Htis, Lm, ENO, total cells, macrophages, neutrophils and lymphocytes in BALF, elastic and collagen fibres compared to controls (p<0.05). In ELABI group, we observed a decrease in Ers ( $37.08 \pm 1.6$  cmH<sub>2</sub>O.mL.<sup>-1</sup>), Rrs ( $0.76 \pm 0.1$  cmH<sub>2</sub>O/mL.<sup>-1</sup>s), Raw ( $0.27 \pm 0.1$  cmH<sub>2</sub>O/mL/s), Htis ( $39.47 \pm 1.7$  cmH<sub>2</sub>O/mL/s(1- $\alpha$ )), Lm ( $58.2 \pm 2.7$   $\mu$ m), elastic content ( $0.34 \pm 0.02$  %), total cells ( $1.17 \pm 0.1$  10<sup>4</sup> cells/mL) and neutrophils ( $0.00 \pm 0.0$  10<sup>4</sup> cells/mL) in BALF compared to ELA group (p<0.05). Conclusions: The treatment with BbCI reduced inflammatory, mechanics and extracellular matrix remodeling alterations induced by elastase. Although more studies need to be performed to elucidate the mechanisms involved in this process, but we may considerate BbCI as a therapeutic tool for COPD management. Supported by: FAPESP, CNPq, LIM-20 HCFMUSP.